Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06383507 Not yet recruiting - Ovarian Cancer Clinical Trials

A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors

Start date: April 22, 2024
Phase: Phase 1
Study type: Interventional

This is a single-center, single-arm ,open-label ,dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or relapsed solid tumors, and obtain recommended doses and infusion patterns.

NCT ID: NCT06367751 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)

LIQPLAT
Start date: May 2024
Phase: N/A
Study type: Interventional

The goal of this study is to assess the implementation and feasibility of ctDNA measurements from blood samples obtained during routine clinical care of cancer patients in the University Hospital Basel. Researchers will compare clinical and patient reported outcomes from the LIQPLAT study with patients who did not receive ctDNA measurements (external comparator from registry AO_2023-00091). Blood samples will be drawn from the patients as part of routine care and ctDNA measurements will be performed on these samples.

NCT ID: NCT06365918 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis

Start date: September 30, 2024
Phase: Phase 1
Study type: Interventional

To find the recommended dose of the investigational drug VG2025 that can be given intraperitoneally (given directly into the abdominal cavity) to participants with advanced solid tumors.

NCT ID: NCT06363201 Not yet recruiting - Sarcoma Clinical Trials

Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours

Start date: April 28, 2024
Phase: N/A
Study type: Interventional

Exploratory study to evaluate the effect and safety of the use of Ocoxin® oral solution on the quality of life of paediatric patients with advanced stage solid tumours.

NCT ID: NCT06362369 Not yet recruiting - Colorectal Cancer Clinical Trials

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Start date: April 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b

NCT ID: NCT06352359 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Start date: June 30, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase I open label, dose-escalation study of intravenous (IV) infusion of ONC-841 as a single agent in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841 starting from 0.03 mg/kg to 30 mg/kg.

NCT ID: NCT06345482 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of MHB039A for Advanced Solid Tumor

Start date: April 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in advanced malignant tumors.

NCT ID: NCT06332170 Not yet recruiting - Clinical trials for Advanced Solid Tumor

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Start date: May 30, 2024
Phase: Phase 1
Study type: Interventional

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients.

NCT ID: NCT06302426 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Trial of INI-4001 in Patients With Advanced Solid Tumours

Start date: March 29, 2024
Phase: Phase 1
Study type: Interventional

Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors.

NCT ID: NCT06298058 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

Start date: March 12, 2024
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A13 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).